Marker Therapeutics, Inc. MRKR
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -34.23%
- 1 year
- -1.01%
- Open
- 1.03
- Prev close
- 1.01
- Mkt cap
- 16.34M
- Vol
- 67.56K
- Avg vol
- 108.06K
- EPS
- -0.42
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.9656
- High
- 1.04
- Forward P/E
- -2.34
- Beta
- 1.49
- Short ratio
- 1.55
- Inst. own
- 22.44%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 27, 2024
- 50-d avg
- 3.71
- 200-d avg
- 3.97
- 1y target
- 19.00
News
-
1 week ago benzinga.com
Marker Therapeutics Secures $2.6M From FDA Through Its Orphan Products Clinical Trials Grants Program To Support Phase 1 Clinical Study Evaluating Lead Investigational MAR-T Cell Therapy, MT-601, In Pancreatic Cancer
Marker Therapeutics, Inc. (NASDAQ:MRKR), is a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies under an exclusive worldwide license from Baylor…
1 week ago globenewswire.com
Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer
HOUSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), is a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies under an…
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Marker Therapeutics (NASDAQ:MRKR) stock increased by 21.2% to $1.11 during Friday's regular session. The market value of their outstanding shares is at $14.8 million. Alaunos Therapeutics…
2 weeks ago zacks.com
All You Need to Know About MARKER THERAPEUTICS (MRKR) Rating Upgrade to Strong Buy
MARKER THERAPEUTICS (MRKR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
2 weeks ago zacks.com
New Strong Buy Stocks for October 16th
UGP, SCSC, MRKR, SLGL and MEOH have been added to the Zacks Rank #1 (Strong Buy) List on October 16, 2026.
1 month ago globenewswire.com
Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies
HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies for the…
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Alector (NASDAQ:ALEC) shares increased by 9.7% to $2.59 during Tuesday's after-market session. The company's market cap stands at $256.8 million. NeuroSense Therapeutics (NASDAQ:NRSN) shares…
4 months ago zacks.com
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
4 months ago zacks.com
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
5 months ago zacks.com
MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?
MARKER THERAPEUTICS (MRKR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
7 months ago zacks.com
MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates
MARKER THERAPEUTICS, INC. (MRKR) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.21.
7 months ago globenewswire.com
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses
8 months ago globenewswire.com
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for…
9 months ago zacks.com
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know
Marker Therapeutics' shares jump 114% in three months as early MT-601 data showed strong responses, advanced into dose expansion, and lifted investor confidence.
9 months ago zacks.com
MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?
After reaching an important support level, MARKER THERAPEUTICS, INC. (MRKR) could be a good stock pick from a technical perspective.
9 months ago zacks.com
5 Small Drug Stocks to Buy as Industry Recovery Picks Up
Innovation is at its peak in the Zacks Medical-Drugs industry. SLNO, NKTR, RIGL, IRWD and MRKR may prove to be good additions to one's portfolio.
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
10 months ago globenewswire.com
Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer
Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with pancreatic cancer in Arm A of the clinical study
11 months ago globenewswire.com
Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma
12 months ago globenewswire.com
Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for…
12 months ago globenewswire.com
Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data
1 year ago globenewswire.com
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatment
1 year ago globenewswire.com
Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for…
1 year ago benzinga.com
Marker Therapeutics Stock Drops After Report About Lymphoma Treatment
Marker Therapeutics, Inc. MRKR on Tuesday provided an update on the progress and clinical observations from the Phase 1 APOLLO study investigating MT-601, a Multi-Antigen Recognizing (MAR)-T cell…
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
3 years ago benzinga.com
Why Apellis Pharmaceuticals Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Monday's Session
Gainers Yellow Corporation (NASDAQ: YELL) shares jumped 106% to $1.46. The trucking company ceased operations on Sunday, according to a Wall Street Journal report.
-
3 years ago benzinga.com
Why Ryanair Holdings Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Tupperware Brands Corporation (NYSE: TUP) shares jumped 59% to $1.43 on above-average volume amid retail investor interest.
-
3 years ago benzinga.com
Why Motorcar Parts of America Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers First Wave BioPharma, Inc. (NASDAQ: FWBI) shares gained 143% to $2.77 after the company achieved its enrollment target for its adrulipase Phase 2 SPAN trial for exocrine pancreatic…
-
3 years ago benzinga.com
Crude Oil Down 2%; Donaldson Shares Drop Following Q3 Results
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 100 points on Wednesday. The Dow traded down 0.34% to 32,929.04 while the NASDAQ fell 0.30% to 12,978.20. The S&P…
-
3 years ago benzinga.com
Why Capri Holdings Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) shares jumped 143% to $0.45 after the company announced it received agreement from the FDA on its proposed single confirmatory Phase 3 study of…
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 93 stocks made new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 175 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's session, 104 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 198 companies hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 497 companies set new 52-week lows.
-
3 years ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
3 years ago benzinga.com
Why Target Shares Are Trading Lower By 14%? Here Are 56 Stocks Moving In Wednesday's Mid-Day Session
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 109% to $0.2115 after dipping around 48% on Tuesday. Fast Radius established a timeline for a Chapter 11 sale process.
-
4 years ago benzinga.com
Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to…
-
4 years ago benzinga.com
Why CinCor Pharma Is Trading Higher By 63%, Here Are 79 Stocks Moving In Monday's Mid-Day Session
Gainers Bonso Electronics International Inc. (NASDAQ: BNSO) shares jumped 132% to $11.12 after jumping around 46% on Friday. The company recently said it expects unaudited comprehensive loss of $1.6…
-
4 years ago benzinga.com
Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday
Gainers
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
Monday's session saw 84 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
During Friday's trading, 69 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 213 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 721 companies achieved new lows for the year.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 313 companies hit new 52-week lows.
-
4 years ago benzinga.com
60 Biggest Movers From Yesterday
Gainers Inspirato Incorporated (NASDAQ: ISPO) shares climbed 618.2% to close at $92.65 on Thursday, just a few days after the company completed its SPAC merger with Thayer Ventures.